Health Financing

Health financing is the study and practice of how money moves through a health system: where it comes from, how it is pooled, how providers are paid, and what that money actually buys.

13 frameworks, from 1883 to today · Global Health · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Health financing is the study and practice of how money moves through a health system: where it comes from, how it is pooled, how providers are paid, and what that money actually buys. It matters because the way a society raises and spends health money determines, often more than any drug or technology, who gets care and who goes without. A country that funds clinics through general taxation and pays doctors salaries will produce a different health system—with different winners and losers—than one that relies on insurance premiums or fees paid at the point of use. The history of the subfield is therefore a history of competing answers to a deceptively simple question: who should pay for health, and on what terms?

Mutual aid, sickness funds, and the invention of social insurance

Before any state ran a health system, workers organized their own. In nineteenth-century Europe, craft guilds and friendly societies collected small regular contributions from members and paid out when someone fell ill or died. These mutual aid arrangements were the seedbed of what became social health insurance: compulsory contributions pooled across a population, with the healthy subsidizing the sick and the wealthy subsidizing the poor.

The decisive turn came in Germany. In 1883, under Chancellor Otto von Bismarck, the state made sickness insurance compulsory for industrial workers, building on existing mutual funds rather than replacing them. The motive was as much political as medical—tying workers to the state against the rising appeal of socialism—but the mechanism proved durable1. Contributions came from employers and employees, were pooled in sickness funds, and paid for medical care and sick pay. The model spread: Austria, Hungary, and others adopted variants before the First World War, and later Japan (1922) and many Latin American countries built contributory systems along similar lines. The core idea—that health costs should be shared across a risk pool rather than borne by the individual—became one of the two great organizing principles of modern health financing.

The Beveridge alternative: health funded from taxation

The second principle crystallized in Britain. In 1942, the economist William Beveridge published a report proposing that want, disease, ignorance, squalor, and idleness be attacked through a comprehensive system of social insurance "from the cradle to the grave." When the National Health Service opened in 1948 under Health Minister Aneurin Bevan, it went further than Beveridge's contributory logic: it was funded overwhelmingly from general taxation, free at the point of use, and available to all residents regardless of contribution history.

This was the tax-funded national health service model, and its financing logic differed sharply from Bismarck's2. There was no separate insurance fund tied to employment; money came from the general public purse, which meant that access did not depend on whether you had a job or had paid in2. The trade-off was that health competed for resources with every other public priority, and rationing happened through budgets and waiting lists rather than through premiums. The Beveridge and Bismarck models—tax-funded versus contributory insurance—became the two poles around which most national health financing debates would organize for the next seventy years. Most real systems, then and now, are hybrids.

User fees and the cost-recovery experiment

As newly independent countries in Africa and Asia built health systems in the 1960s and 1970s, many provided care free or nearly free at public facilities. That changed in the 1980s. Facing debt crises and structural adjustment programs imposed by international lenders, governments cut public spending, and international agencies promoted user fees—charges paid by patients at the point of care—as a way to recover costs and, it was argued, improve efficiency and quality.

The World Bank's 1993 World Development Report, Investing in Health, gave this approach an influential intellectual framework, ranking health interventions by cost-effectiveness and urging governments to concentrate public money on the most efficient ones while charging patients for the rest. The logic was that fees would generate revenue, discourage frivolous use, and make facilities responsive to patients. In practice, the evidence that accumulated through the 1990s and 2000s told a different story: fees deterred the poor from seeking care, including for serious illness, and revenue recovered was often modest. The experience became a cautionary tale that shaped the next generation of thinking—and helped push the field toward prepayment and pooling as the preferred route.

Primary health care and the Alma-Ata promise

In 1978, at Alma-Ata in Kazakhstan, the World Health Organization and UNICEF convened governments around a vision of primary health care: essential care made universally accessible through community participation, intersectoral action, and—crucially for financing—affordable, equitable funding. The declaration's slogan, "Health for All by the Year 2000," implied that financing had to be organized around universal access rather than ability to pay.

The vision was contested almost immediately. A rival approach, later called selective primary health care, argued that scarce resources should fund a small set of highly cost-effective interventions—oral rehydration, immunization, breastfeeding promotion—rather than comprehensive services. The 1979 "Health and Population in Development" work associated with the Rockefeller Foundation gave this view its intellectual footing. The debate between comprehensive and selective primary health care was, at bottom, a financing argument: should money go to building broad, publicly funded systems, or to targeted, measurable packages? The selective approach won much of the 1980s, shaping how donors spent and what they expected to see for their money.

Vertical campaigns and the rise of the global aid architecture

Alongside these system-level debates, a parallel financing logic grew around single diseases. Vertical disease campaign financing—money raised and spent against one disease, with its own targets, staff, and delivery channels—scored historic successes. The campaign to eradicate smallpox, completed in 1980, showed what concentrated financing could achieve. Later, the Onchocerciasis Control Programme in West Africa and the Guinea Worm Eradication Program demonstrated that sustained, targeted funding could push a disease toward elimination.

The scale changed at the turn of the millennium. New institutions pooled money from wealthy governments, foundations, and private donors and directed it at specific problems. The Global Fund to Fight AIDS, Tuberculosis and Malaria, created in 2002, and Gavi, the Vaccine Alliance, founded in 2000, became the archetypes: large, performance-oriented, and focused on measurable results345. The President's Emergency Plan for AIDS Relief (PEPFAR), launched by the United States in 2003, added billions more. This global aid architecture transformed what low-income countries could finance—antiretroviral treatment for millions of people became possible—but it also raised hard questions. Vertical money could distort national priorities, pull health workers toward donor-funded programs, and leave governments with recurrent costs they could not sustain once a grant ended.

Aid effectiveness and the ownership problem

By the mid-2000s, frustration with fragmented, donor-driven financing produced a reform movement. The 2005 Paris Declaration on Aid Effectiveness set out principles—country ownership, alignment of donor money with national plans, harmonization among donors, managing for results, and mutual accountability—that reframed the question from "how much aid" to "how aid is governed." The follow-up Accra Agenda for Action in 2008 pushed further on predictability and use of country systems.

The practical expression was sector-wide approaches and, in health, sector-wide approaches (SWAps) and later the International Health Partnership, which tried to channel donor money through a single national health plan and budget rather than dozens of separate projects. The appeal was coherence; the difficulty was that donors still wanted to see their own money produce visible results, and governments often lacked the public financial management systems to absorb pooled funds transparently. The tension between donor accountability and country ownership has never been fully resolved.

Results-based financing: paying for outcomes

A more recent turn asked whether money should be tied not to inputs—staff, buildings, drugs—but to results. Results-based financing covers a family of arrangements in which payment is conditional on delivering specified outputs or outcomes: a facility receives a bonus for each verified institutional delivery, or a government receives a tranche of aid when coverage targets are met6. The approach drew on performance-based contracting experiments and on the logic of aligning incentives with measurable goals.

Proponents argued it improved accountability and directed effort toward things that could be counted. Critics worried about gaming, about neglect of hard-to-measure dimensions of care, and about whether the gains persisted once payments stopped. The evidence base grew through dozens of pilot programs and evaluations, and the debate became one of the field's most active—an argument less about whether incentives matter than about which ones, at what cost, and for whom.

Cost-effectiveness and the priority-setting toolkit

Running through all of this was a technical revolution in how to decide what to fund. Cost-effectiveness analysis compares the cost of an intervention against the health it produces, often expressed as cost per disability-adjusted life year (DALY) averted—a metric that combines years of life lost to premature death with years lived in disability78. The approach, developed through the 1980s and 1990s and given global prominence by the World Bank's 1993 report and later by the Disease Control Priorities project, gave governments and donors a common yardstick.

Its power was that it made trade-offs explicit: if intervention A buys more health per dollar than intervention B, funding B instead of A has an opportunity cost measured in lives. Its limitation was that the yardstick says nothing about equity, about who bears the cost, or about whether the things that are hard to measure—trust, continuity, dignity—matter. Priority-setting bodies in several countries, and later initiatives such as the WHO's CHOICE project, built cost-effectiveness into formal benefit packages, but the gap between what is cost-effective and what is politically and ethically acceptable remained a persistent theme.

Universal health coverage as the organizing goal

The strands converged in the 2010s around universal health coverage (UHC): the principle that everyone should receive needed health services without financial hardship. The 2010 World Health Report framed UHC as a financing problem of three dimensions—population covered, services covered, and proportion of costs covered—and the idea was written into the Sustainable Development Goals in 2015 as target 3.8.

UHC gave the field a shared destination and a way to measure progress: catastrophic health expenditure, the share of households spending a large fraction of their income on care, became a standard indicator. It also revived the old Bismarck-versus-Beveridge question in new settings, as countries such as Thailand, Mexico, and Indonesia expanded coverage through combinations of tax funding and contributory schemes. Community-based health insurance—voluntary, locally pooled prepayment schemes, often in rural areas—was tried widely as a stepping stone, particularly in sub-Saharan Africa and Asia; evaluations generally found enrollment and financial protection modest, and many schemes came to be seen as transitional rather than sufficient on their own.

Where the field stands

Today health financing works with a recognizable toolkit: revenue raising (taxes, contributions, premiums, donor money), pooling (the consolidation of funds to spread risk), purchasing (how providers are paid—salaries, capitation, fee-for-service, case-based payment), and benefit design (what is covered and for whom). The field's central instruments—national health accounts, costing models, cost-effectiveness analysis, financial protection indicators—descend directly from the debates above. The open questions are the old ones in new clothes: how to expand prepaid pooling in countries with large informal workforces, how to move donor-dependent systems toward domestic financing without losing coverage, how to pay providers for quality rather than volume, and how to reconcile the efficiency logic of cost-effectiveness with the equity promise of universal coverage. The argument over who pays, and on what terms, is not settled; it is the field's ongoing work.

References

  1. Bismarck model (History), Wikipedia
  2. Beveridge model, Wikipedia
  3. Global health (History), Wikipedia
  4. The Global Fund to Fight AIDS, Tuberculosis and Malaria, Wikipedia
  5. GAVI (History and programs), Wikipedia
  6. Pay for performance (healthcare), Wikipedia
  7. Cost-effectiveness analysis, Wikipedia
  8. Disability-adjusted life year, Wikipedia

The frameworks of Health Financing

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1883-Present

    Bismarck model

    Who should pay for sickness care?

    Fly to its tower in Nousfarer

  2. 1942-Present

    Beveridge model

    Should health care be funded from taxes?

    Fly to its tower in Nousfarer

  3. 1966-Present
  4. 1978-1990

    Comprehensive primary health care

    Should everyone get comprehensive basic care?

    Fly to its tower in Nousfarer

  5. 1979-1995

    Selective primary health care

    Should funds buy only the most effective interventions?

    Fly to its tower in Nousfarer

  6. 1980-2005

    User fees and cost recovery

    Should patients pay at the point of care?

    Fly to its tower in Nousfarer

  7. 1985-Present

    Cost-effectiveness analysis

    Which interventions give most health per dollar?

    Fly to its tower in Nousfarer

  8. 1990-Present

    Community-based health insurance

    Can communities pool money against illness?

    Fly to its tower in Nousfarer

  9. 2000-Present
  10. 2000-Present

    Health financing functions framework

    How does money move through a health system?

    Fly to its tower in Nousfarer

  11. 2000-Present

    Pay for performance

    Should providers be paid for results?

    Fly to its tower in Nousfarer

  12. 2005-Present
  13. 2010-Present

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Bismarck modelBeveridge modelVertical disease campaign financingComprehensive primary health careSelective primary health careUser fees and cost recoveryCost-effectiveness analysisCommunity-based health insuranceGlobal health aid architectureHealth financing functions frameworkPay for performanceAid effectiveness and country ownersh…Universal health care

Beyond the field

Where Health Financing's ideas came from in other fields, and what they led to there: the strongest 12 of 77 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Health Financing is a planet in Nousfarer

Its city has a tower for each of these 13 frameworks. Land, walk in, and climb one concept at a time.

Land on Health Financing

Related fields

Fields its ideas are linked to

More in Global Health

See where Health Financing sits on the Map of Human Knowledge